Browse the corpus

Hydrocodone is a semi-synthetic opioid medication that is classified as a schedule II drug. This medication is approved by the U.S. Food and Drug Administration (FDA) and used for pain management. Hydrocodone is primarily used to treat severe chronic pain that requires opioid analgesia and is not effectively treated by nonopioid alternatives. Hydrocodone is used in combination formulations to treat nonproductive cough in adults and has antitussive properties. Hydrocodone functions as an opioid receptor agonist and activates mu-opioid receptors to produce analgesic effects. In addition, hydrocodone activates delta- and kappa-opioid receptors as the plasma drug concentration increases beyond the starting doses. This activity outlines the indications, mechanism of action, significant adverse effects, contraindications, monitoring, and toxicity of hydrocodone in the clinical setting pertaining to pain relief. An interprofessional team comprising emergency medicine, critical care, and primary care would enhance the outcomes of patients with pain, related conditions, and sequelae. Given the opioid misuse epidemic in the United States, the emphasis on patient-centered care is important. Objectives: Identify appropriate indications for hydrocodone, distinguishing use in severe chronic pain and nonproductive cough in adults. Assess patients for pain relief while monitoring both the effectiveness of hydrocodone and any potential adverse effects, signs of misuse, or addiction. Select the most appropriate formulation and strength of hydrocodone based on the pain intensity, duration, and individual needs, considering factors such as age, renal or hepatic impairment, and potential drug interactions. Collaborate with an interprofessional healthcare team to optimize comprehensive care in patients undergoing hydrocodone therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose The signs and symptoms of hydrocodone toxicity include apnea, breathing difficulties, bradycardia, miosis, clammy skin, cyanosis, hypotension, decreased level of consciousness, and loss of consciousness. Overdose-related pulmonary complications include noncardiogenic pulmonary edema and aspiration pneumonitis. Central respiratory depression leading to CO2 retention often results in respiratory acidosis. Management of Overdose The antidote for overdose is an opioid antagonist medication. Clinicians should administer IV naloxone for hydrocodone overdose. Naloxone can be administered through IV, intramuscular (IM), intranasal, subcutaneous (SC), and endotracheal routes. Patients with low respiratory rates or apnea should receive an initial dose of 0.4 to 2 mg of naloxone. For patients who develop respiratory failure, administration of 2 mg of naloxone is recommended. Naloxone dosing may be repeated every 2 to 3 minutes, depending on the clinical response. If the patient shows signs of opioid withdrawal, the naloxone infusion should be discontinued.[39] Opioid receptors are G-protein-coupled receptors. Agonist stimulation inhibits cAMP formation, inhibiting the release of nociceptive neurotransmitters, postsynaptic neuronal hyperpolarization, and reduced neuronal excitability.[5][6][7] Naloxone, a highly competitive mu-receptor antagonist, reverses the inhibition of cAMP formation and nociceptive neurotransmitter release and reverses postsynaptic neuronal hyperpolarization, reducing neuronal excitability. This reversal extends to clinical signs and symptoms of opioid toxicity, including respiratory depression and decreased level of consciousness. The indication for airway management is severe respiratory depression or apnea secondary to hydrocodone toxicity. In acute respiratory distress syndrome cases, management involves ensuring adequate oxygenation, utilizing low tidal volume ventilation, and applying high positive end-expiratory pressure (PEEP). Caution is essential to prevent ventilator-induced lung injury.[40] Patients who have taken ER preparations require prolonged monitoring after the reversal, as delayed absorption of hydrocodone is possible. Emergency department clinicians should refer stabilized patients to psychiatric evaluation.

The indication for airway management is severe respiratory depression or apnea secondary to hydrocodone toxicity. In acute respiratory distress syndrome cases, management involves ensuring adequate oxygenation, utilizing low tidal volume ventilation, and applying high positive end-expiratory pressure (PEEP). Caution is essential to prevent ventilator-induced lung injury.[40] Patients who have taken ER preparations require prolonged monitoring after the reversal, as delayed absorption of hydrocodone is possible. Emergency department clinicians should refer stabilized patients to psychiatric evaluation. The FDA has approved hydrocodone formulations with abuse-deterrent properties. These formulations deter misuse by preventing chewing, injecting, or snorting.[41] Hydrocodone can cause life-threatening secondary adrenal insufficiency, which requires immediate corticosteroid replacement.[28]

The optimal strategy involves an interprofessional approach to prescribing and administering hydrocodone. Healthcare professionals should be knowledgeable about the appropriate indications, adverse drug reactions, and toxicity management to ensure optimal patient outcomes for hydrocodone therapy. In September 2018, the FDA mandated the Risk Evaluation and Mitigation Strategy (REMS) training program for all drug company personnel involved with approved opioid analgesics to mitigate the abuse and misuse of opioid analgesics, including hydrocodone. This program requires all clinicians, including physicians, mid-level practitioners, nurses, and pharmacists responsible for pain management in patients, to undergo training on the fundamentals of acute and chronic pain management and the safe use and risks of opioids.[42] The American Geriatrics Society (AGS) Beers Criteria highlights potentially inappropriate medications for geriatric patients. According to a study, hydrocodone/acetaminophen was among the most frequently prescribed medications associated with emergency room visits.[43][44] Ideally, clinicians should prescribe hydrocodone for appropriate indications, carefully weighing therapy's associated risks and benefits. Furthermore, they should routinely monitor the necessity for hydrocodone at each visit and assess for any aberrant behavior. When prescribing hydrocodone for cough, clinicians should thoroughly investigate and rule out conditions such as gastroesophageal reflux disease (GERD) and other disorders that may contribute to coughing.[45] The Prescription Drug Monitoring Program (PDMP) is an electronic database tracking controlled substance prescriptions. Clinicians should consult the database before prescribing hydrocodone to prevent multiple refills. Notably, information regarding methadone from opiate treatment programs is not accessible in the PDMP.[46] In addition, pharmacists should counsel patients regarding the adverse drug reactions associated with hydrocodone therapy and ensure proper dosing, considering hepatic and renal function. Pharmacists should communicate with the prescribing clinician if any uncertainties arise, such as requests for early refills. Similarly, nurses should assess pain levels during each visit, evaluate the effectiveness of treatment, and remain vigilant for signs of adverse events or misuse.

The Prescription Drug Monitoring Program (PDMP) is an electronic database tracking controlled substance prescriptions. Clinicians should consult the database before prescribing hydrocodone to prevent multiple refills. Notably, information regarding methadone from opiate treatment programs is not accessible in the PDMP.[46] In addition, pharmacists should counsel patients regarding the adverse drug reactions associated with hydrocodone therapy and ensure proper dosing, considering hepatic and renal function. Pharmacists should communicate with the prescribing clinician if any uncertainties arise, such as requests for early refills. Similarly, nurses should assess pain levels during each visit, evaluate the effectiveness of treatment, and remain vigilant for signs of adverse events or misuse. In the case of a hydrocodone overdose, triage nurses should admit the patient and promptly inform the emergency department clinician. The clinician should order urine drug levels, analyze arterial blood gases, monitor the patient for respiratory depression, and consider naloxone or activated charcoal therapy as indicated. Patients experiencing severe respiratory depression and paralytic ileus may necessitate intensive care unit (ICU) care. When the patient stabilizes, they can be referred to a psychiatrist and/or mental health counselor, especially if the overdose is deliberate.[47] The clinician should refer the patient for detoxification upon diagnosing opioid use disorder. Subsequent referral for medication-assisted treatment (MAT) and psychosocial treatment is essential to prevent relapse.[48] Multiple clinicians are usually involved in patient care. Therefore, collaborative efforts are necessary to achieve optimal outcomes. An interprofessional team approach, characterized by open communication and shared decision-making, will optimize therapeutic efficacy and minimize adverse drug reactions associated with hydrocodone therapy, enhancing patient outcomes.